Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Pharm-Olam Blog

News

Pharm-Olam is singularly committed to optimizing every aspect of a clinical trial across all functional areas. We have enrolled thousands of patients in planned studies and have been frequently enlisted for rescue studies, assistance with data protection and US federal funding for clinical research.

Blog Feature

Infectious Disease & Vaccines | Press Release | COVID-19

By: Pharm-Olam
March 26th, 2020

TORONTO, March 25, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases, is pleased to announce that the Company has retained Pharm-Olam, LLC, with proven clinical experience in infectious diseases completing over 100 clinical studies in approximately 19,000 patients at over 2,000 clinical sites, to serve as the Company’s Contract Research Organization (“CRO”) to advance the future clinical study for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (“COVID-19”).  In addition, Revive has added Dr. Kelly McKee, Jr., MD, MPH as Chief Scientific Officer consultant and Dr. Onesmo Mpanju, PhD as Regulatory Affairs consultant to the Company’s clinical development team.